Health

First participant administered in a study evaluating COVID-19 booster candidates for the modelna vaccine

In an ongoing Phase 2 clinical trial, patients are beginning to be vaccinated with a modified version of Moderna’s COVID-19 vaccine.

An ongoing Phase II clinical trial has modified Moderna’s COVID-19 vaccine, called mRNA-1273.351, to address the potential need for booster vaccine candidates in the light of the emergence of SARS-CoV-2 variants. The version started vaccination of patients.

The company’s modified vaccine was developed to target the SARS-CoV-2 mutant B.1.351, which was first identified in South Africa. However, mRNA-1273.351 is also being evaluated as a potential booster vaccine for other new variants with mutations in the key receptor binding domain.

Modified vaccines are multivalued candidates that combine Moderna’s previously approved vaccines, mRNA-1273 and mRNA-1273.351, into a single vaccine. The combination of both candidates is designed to elicit a broad immune response that can serve as a major series of initial vaccinations for patients and as a boost to patients who have previously been vaccinated with mRNA-1273.

In a previous study, vaccination with mRNA-1273 had neutralizing titers for all major variants tested, including variant B.1.1.7 and variant B.1.351, which were first identified in the United Kingdom. It is shown to be generated. The study found that the neutralizing titer, especially for B.1.351, was further reduced by a factor of 6.

However, despite the efficacy of mRNA-1273 against these new mutants, Moderna establishes a clinical development strategy that modifies ongoing Phase 2 trials to specifically address the new mutants. I decided that. The study enrolled 60 participants who were previously vaccinated with mRNA-1273 and were candidates for variant-specific boosters to target the B.1.351 variant mRNA-1273.351 20 µg, mRNA-1273.351 50 µg, or A 50 µg multivalent booster candidate mRNA-1273.211 that combines mRNA-1273 and mRNA-1273.351 in a single vaccine.

In a previous revision of an ongoing Phase 2 clinical trial, participants vaccinated with mRNA-1273 received a single dose of a 50 µg booster immunodose of mRNA-1273. However, the results of this protocol extension have not been published as administration is ongoing.

In addition to trials evaluating the multivalent modified mRNA-1273.351, the National Institute of Allergy and Infectious Diseases (NIAID) is a Phase 1 clinical trial designed to investigate the use of primary and polyvalent modified mRNA-1273 vaccines. Is also carried out. As a series of vaccine-inexperienced individuals, and as a booster vaccine for people previously vaccinated with mRNA-1273. However, this study has not yet begun, as NIAID is awaiting approval from the FDA to proceed safely.

reference

Moderna announced the first participants to participate in a study evaluating COVID-19 booster vaccine candidates. Cambridge, Massachusetts: Moderna; March 10, 2021. https://www.businesswire.com/news/home/20210310005932/en.. Accessed on March 11, 2021.

ExBulletin

First participant administered in a study evaluating COVID-19 booster candidates for the modelna vaccine